Suchergebnisse - "Brufsky, Adam"

PubPharm (284)

1

Organizational Breast Cancer Data Mart : A Solution for Assessing Outcomes of Imaging and Treatment

enthalten in: JCO clinical cancer informatics | 2024

von Zuley, M. | Silverstein, J. | Logue, D. | +6

2

Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Geyer, C. | Blum, J. | Yothers, G. | +18

3

Omission of surgery, primary endocrine therapy adherence, and effect of comorbidity in older women with estrogen receptor positive breast cancer

enthalten in: Journal of geriatric oncology | 2024

von Carleton, N. | Abidi, H. | Puthanmadhom-Narayanan, S. | +6

4

Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor : a plain language summary

enthalten in: Future oncology (London, England) | 2024

von Brufsky, A. | Liu, X. | Li, B. | +4

5

Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice : a plain language summary of a real-world database study

enthalten in: Future oncology (London, England) | 2024

von Rugo, H. | Liu, X. | Li, B. | +5

6

Health-related quality of life over chemotherapy course among individuals with early-stage breast cancer : the association of social determinants of health and neighborhood socioeconomic disadvantage

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2024

von You, K. | Sereika, S. | Bender, C. | +4

7

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802) : a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial

enthalten in: The Lancet. Oncology | 2024

von Palmieri, C. | Linden, H. | Birrell, S. | +12

ErratumIn: Lancet Oncol. 2024 Apr;25(4):e137. - PMID 38547897

8

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Bardia, A. | Rugo, H. | Tolaney, S. | +17

9

Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Mamounas, E. | Bandos, H. | Rastogi, P. | +15

10

Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database

enthalten in: International journal of cancer | 2024

von Rugo, H. | Liu, X. | Li, B. | +4

ErratumIn: Int J Cancer. 2024 Mar 30;:. - PMID 38554278

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[29]